ClinicalTrials.gg
CompletedNCT01562743RLSUpdated Apr 23, 2014Results posted

A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome

A Phase 2 interventional study of SPM 962 in Idiopathic Restless Legs Syndrome, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-04-23.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Not applicable
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
8th of 19
185 · median 130
Started
2008
with 1 other
Phase 2
6 of 19
none open now
Registered
14th of 19
by date
Lead sponsor
3 of 19
Otsuka Pharmaceutical Co., Ltd.

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 8th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 14th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

The aims of the trial are to assess the safety and the efficacy of SPM 962 following once-a-daily transdermal administration within a range of 2.25 to 6.75 mg/day in Japanese patients with restless legs syndrome (RLS) in a multi-center, open-label trial. The maximum treatment period is 53 weeks. The trial is an extension trial from the precedent 6-week, double-blind, randomized, placebo-controlled, parallel-group comparative trial(243-07-003). The trial is also for an exploratory investigation of incidence of augmentation, the most problematic complications in dopaminergic treatment.

03

Conditions studied

  • Idiopathic Restless Legs Syndrome
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed the preceding trial 243-07-003 (NCT00666965)

Exclusion criteria

Exclusion Criteria:

  • Subject discontinued from the preceding trial 243-07-003 (NCT00666965)
  • Subject had a serious adverse event which association with the drug is not ruled out during trial 243-07-003
  • Subject had a persistent serious adverse event at the baseline, which was observed and association with the investigational drug is ruled out during trial 243-07-003.
  • Subject had persistent hallucination or delusion during trial 243-07-003.
  • Subject had psychiatric conditions such as confusion, excitation, delirium, abnormal behaviour at the baseline.
  • Subject had orthostatic hypotension or a systolic blood pressure (SBP) ≤ 100 mmHg and had a decrease of SBP from spine to standing position ≥ 30 mmHg at baseline.
  • Subject had a history of epilepsy, convulsion etc. during trial 243-07-003.
  • Subject developed serious abnormality at the baseline.
  • Subject had -interval ≥ 500 msec at the baseline or subject had an increase of QTc-interval ≥ 60 msec from the baseline in the trial 243-07-003 and had a QTc-interval > 470 msec in female or > 450 msec in male at the baseline.
  • Subject had a serum potassium level \< 3.5 mEq/L at the end of the taper period in trial 243-07-003.
  • Subject had a total ≥ 3.0 mg/dL or (GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or ≥ 100 IU/L) at the end of the period in trial 243-07-003.
  • Subject had BUN ≥ 30 mg/dL or serum creatinine ≥ 2.0 mg/dl at the end of the taper period in trial 243-07-003.
  • Subject who planned pregnancy during the trial.
  • Subject was judged to be inappropriate for this trial by the investigator for the reasons other than above.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    SPM 962

    Rotigotine transdermal patch

    Drug: SPM 962

Interventions

  • Tansdermal patch

    Also known as: rotigotine

06

What researchers measure

Primary outcomes

  1. The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters

    The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of adverse events, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below: 1. sudden onset of sleep 2. obsessive-compulsive disorder or impulse-control disorder 3. hallucination, delusion

    Time frame: Up to 54 weeks

  2. Augmentation

    Augmentation is the main complication during long-term dopaminergic treatment of restless legs syndrome (RLS) and reflects an overall increase in RLS severity. Augmentation is clinically significant when at least one of the following occurs: 1. Change in daily activities and/or behavior (e.g., the patient stops riding in cars in the afternoon) due to augmentation; 2. Negative impact on the patient's quality of life (sleep, mood, etc.) due to augmentation; 3. Need to change the treatment dose or the patient needs to take the dose earlier in the day (e.g., dividing the dose); 4. Adjustments in concomitant medication are made to compensate for augmented RLS symptoms (e.g., an increased intake of analgesics or hypnotics to cover an increase in symptom intensity); 5. Any other aspect as judged by the evaluator (should be specified).

    Time frame: Up to 53 weeks

  3. Change of the Pittsburgh Sleep Quality Index (PSQI) From Baseline to Each Visit

    PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement.

    Time frame: Baseline, Up to 53 weeks

Secondary outcomes

  1. Change of IRLS Sum Score From the Baseline to Each Visit

    IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.

    Time frame: Baseline, Up to 53 weeks

  2. Efficacy Rate in IRLS Sum Score

    Efficacy rate (percentage of subjects with 50% decrease) (LOCF) in IRLS sum score.

    Time frame: Baseline, Up to 53 weeks

  3. Change of Augmentation Severity Rating Scale (ASRS) Sum Score From Baseline to Each Visit

    ASRS is a scale for assessing severity of augmentation. ASRS consists of 3 items (one item containing 4 sub-items). The sum of the score of each question serves as the scale score (each question score: 0-3, sum score 0-24). A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, Up to 52 weeks

  4. Change of Short-Form 36-Item Health Survey (SF-36) From Baseline to Each Visit

    SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.

    Time frame: Baseline, Up to 53 weeks

07

Results

Posted Apr 23, 2014

Participant flow

Participant flow — Overall Study
MilestoneSPM 962
Started185
Completed133
Not completed52
Withdrew: Adverse event29
Withdrew: Lack of efficacy3
Withdrew: Withdrawal by subject13
Withdrew: Protocol violation1
Withdrew: Discontinuation criteria2
Withdrew: Lost to follow-up2
Withdrew: Physician decision2

Outcome measures

PrimaryThe Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters

The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of adverse events, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below: 1. sudden onset of sleep 2. obsessive-compulsive disorder or impulse-control disorder 3. hallucination, delusion

Time frame:
Up to 54 weeks
Reported as:
Number · participants
The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters
participantsSPM 962
Any AEs175
Treatment-related AEs139
SAEs5
Treatment-related SAEs1
Severe AEs3
Discontinuation due to AEs29
Death0
AEs of special interest 10
AEs of special interest 20
AEs of special interest 30
Valvular disease of the heart0
PrimaryAugmentation

Augmentation is the main complication during long-term dopaminergic treatment of restless legs syndrome (RLS) and reflects an overall increase in RLS severity. Augmentation is clinically significant when at least one of the following occurs: 1. Change in daily activities and/or behavior (e.g., the patient stops riding in cars in the afternoon) due to augmentation; 2. Negative impact on the patient's quality of life (sleep, mood, etc.) due to augmentation; 3. Need to change the treatment dose or the patient needs to take the dose earlier in the day (e.g., dividing the dose); 4. Adjustments in concomitant medication are made to compensate for augmented RLS symptoms (e.g., an increased intake of analgesics or hypnotics to cover an increase in symptom intensity); 5. Any other aspect as judged by the evaluator (should be specified).

Time frame:
Up to 53 weeks
Reported as:
Number · participants
Augmentation
participantsSPM 962
Subjects with augmentation11
Subjects with clinically significant augmentation5
SecondaryChange of IRLS Sum Score From the Baseline to Each Visit

IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.

Time frame:
Baseline, Up to 53 weeks
Reported as:
Mean · Scores on a scale
Change of IRLS Sum Score From the Baseline to Each Visit
Scores on a scaleSPM 962
Weeks 8-11.4 ± 8.8
Week 16-9.7 ± 9.6
Week 32-9.5 ± 9.1
Week 44-10.4 ± 9.1
SecondaryEfficacy Rate in IRLS Sum Score

Efficacy rate (percentage of subjects with 50% decrease) (LOCF) in IRLS sum score.

Time frame:
Baseline, Up to 53 weeks
Reported as:
Number · Percentage of participants
Efficacy Rate in IRLS Sum Score
Percentage of participantsSPM 962
Weeks 864.1 (57.2 to 71.1)
Week 1654.9 (47.7 to 62.1)
Week 3257.6 (50.5 to 64.7)
Week 4460.3 (53.3 to 67.4)
SecondaryChange of Augmentation Severity Rating Scale (ASRS) Sum Score From Baseline to Each Visit

ASRS is a scale for assessing severity of augmentation. ASRS consists of 3 items (one item containing 4 sub-items). The sum of the score of each question serves as the scale score (each question score: 0-3, sum score 0-24). A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, Up to 52 weeks
Reported as:
Mean · Scores on a scale
Change of Augmentation Severity Rating Scale (ASRS) Sum Score From Baseline to Each Visit
Scores on a scaleSPM 962
Week 81.4 ± 2.5
Week 161.4 ± 2.6
Week 321.6 ± 2.7
Week 441.4 ± 2.6
PrimaryChange of the Pittsburgh Sleep Quality Index (PSQI) From Baseline to Each Visit

PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement.

Time frame:
Baseline, Up to 53 weeks
Reported as:
Mean · Scores on a scale
Change of the Pittsburgh Sleep Quality Index (PSQI) From Baseline to Each Visit
Scores on a scaleSPM 962
Week 8-2.2 ± 3.3
Week 16-2.2 ± 2.9
Week 44-2.0 ± 3.1
SecondaryChange of Short-Form 36-Item Health Survey (SF-36) From Baseline to Each Visit

SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.

Time frame:
Baseline, Up to 53 weeks
Reported as:
Mean · Scores on a scale
Change of Short-Form 36-Item Health Survey (SF-36) From Baseline to Each Visit
Scores on a scaleSPM 962
Physical functioning-0.2 ± 8.0
Role physical3.7 ± 17.4
Bodily pain5.1 ± 22.3
General health1.8 ± 12.8
Vitality4.9 ± 15.8
Social functioning3.0 ± 16.2
Role emotional5.6 ± 14.5

Adverse events

Collected over 53 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPM 962—5/185 (2.7%)165/185 (89.2%)
Most frequent serious events
Most frequent serious events
EventSPM 962
CataractEye disorders1/185
Diverticulitis Intestinal HaemorrhagicGastrointestinal disorders1/185
Application Site DiscolourationGeneral disorders1/185
ContusionInjury, poisoning and procedural complications1/185
Neck CrushingInjury, poisoning and procedural complications1/185
Nerve Root Injury LumbarInjury, poisoning and procedural complications1/185
Traffic AccidentInjury, poisoning and procedural complications1/185
HaematomaVascular disorders1/185
Most frequent other events
Showing 10 of 18
Most frequent other events
EventSPM 962
NasopharyngitisInfections and infestations97/185
Application Site ReactionGeneral disorders85/185
NauseaGastrointestinal disorders53/185
SomnolencePsychiatric disorders29/185
HeadacheNervous system disorders25/185
VomitingGastrointestinal disorders15/185
DiarrhoeaGastrointestinal disorders12/185
Application Site PruritusGeneral disorders12/185
FallInjury, poisoning and procedural complications11/185
Abdominal Pain UpperGastrointestinal disorders10/185

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SPM 962
<=18 years0
Between 18 and 65 years157
>=65 years28
Age, Continuous
Age, Continuous(years)SPM 962
Mean49.8 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)SPM 962
Female113
Male72
Region of Enrollment
Region of Enrollment(participants)SPM 962
Japan185
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Inoue Y, Hirata K, Hayashida K, Hattori N, Tomida T, Garcia-Borreguero D; Rotigotine Study Group. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:326-33. doi: 10.1016/j.pnpbp.2012.10.012. Epub 2012 Oct 25. PubMed 23103551 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2012
First posted
Mar 26, 2012
Start
Aug 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Apr 23, 2014
Last update
Apr 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01562743
Responsible party
Sponsor
First posted
Mar 26, 2012
Start date
Aug 2008
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Apr 23, 2014
Last update
Apr 23, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion